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ABSTRACT
C-Reactive protein (CRP) is a major acute-phase
response protein, which is activated by various
cytokines. We investigated the mechanism of
TNF-a-induced CRP expression and found that the
p50 subunit of NF-iB was responsible for the
transcriptional activation of CRP. Since the p50
protein acts as a positive regulator of CRP expres-
sion without an inherent transactivation domain, we
looked for an interaction partner that could provide
p50 with such a domain. We found that b-catenin
enhanced the expression of a CRP mRNA in concert
with p50 subunit. Protein–protein interaction
between p50 and b-catenin was important for CRP
expression and their interactions to CRP promoter
were induced after TNF-a treatment. Since gene
expression depends upon the proximity of promot-
ers and distal regulatory sites, we explored the
long-range genomic interaction at the CRP locus by
chromosome conformation capture (3C). We identi-
fied a binding site for b-catenin in the downstream of
CRP gene by 3C and confirmed TNF-a-induced
association of b-catenin and p50 by chromatin
immunoprecipitation and co-immunoprecipitation
assays. Our findings provide evidence that tran-
scription of the CRP gene depends upon p50 and
b-catenin proteins, which is accompanied by close
proximity between promoter and the downstream
region of CRP gene.
INTRODUCTION
NF-kB/Rel is a critical transcription factor controlling
innate immunity, inﬂammation, cell survival and tumor-
igenesis (1–3). There are ﬁve structurally related members
of the mammalian NF-kB/Rel family of proteins: p50,
p52, p65/Rel A, Rel B and c-Rel. Genetic analysis has
revealed the functional speciﬁcities of these NF-kB
subunits and shown that the formation of dimers of
NF-kB subunits and the exchange of subunits are
important for modulating NF-kB activity (4). To
understand the functional speciﬁcity of NF-kB target
genes, it is necessary to identify protein–protein as well
as DNA–protein interactions involving the NF-kB
subunits and its target DNA elements.
Although the p65 subunit of NF-kB is the major
transcriptional activator of many of NF-kB target genes,
other subunits are likely to play important roles in
particular NF-kB-mediated processes. For example, the
p50 and p52 subunits of NF-kB appear to be important
in inﬂammation and apoptosis (5,6). In some cases, p50
by itself without a bound p65 subunit, actually activates
transcription of target genes. Because it is unusual for
proteins without associated transactivation domains to
activate transcription, it is likely that transcriptional
co-activators are involved in this p50-mediated transcrip-
tion (7). Hence identiﬁcation of transcriptional
co-activators of the p50 subunit should throw light on
its target gene speciﬁcity.
Several natural promoters have been reported to be
activated by the p50 subunit but not by the p65 subunit.
We chose the C-reactive protein (CRP) promoter as a
model for p50-dependent transcription (8). CRP is a major
human acute-phase protein whose rate of synthesis can
increase in inﬂammatory states (9). There is increasing
evidence that it is not merely an important risk marker but
also has a role in the pathogenesis of atherosclerosis (10).
It is induced by various cytokines, such as interleukin-6
(IL-6), interleukin-1 (IL-1) and TNF-a (11). It was
previously proposed that IL-6 stimulates CRP expression,
and one of the non-consensus kB sites overlapping the
C/EBP-binding site was identiﬁed as a p50-responsive
element (12). Even though it has been proposed that
NF-kB p50 subunit plays important roles in CRP
expression, the transcriptional activator for p50 protein
has not been identiﬁed in the cases of these inﬂammatory
signals.
b-Catenin is a multifunctional protein that plays critical
roles in cell adhesion as well as Wnt-activated tumorigen-
esis (13). When b-catenin levels rise, it accumulates in the
nucleus, where it interacts with DNA-bound TCF/LEF
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target genes. b-Catenin binds to diverse proteins respon-
sible for speciﬁc transcriptional regulation and chromatin
remodeling in the nucleus; however, the nuclear protein
complexes involving b-catenin remain to be identiﬁed.
It is especially important to decipher protein–protein
interaction on the speciﬁc target genes of b-catenin.
We searched for a transcriptional co-activator that
might provide p50 with a transactivation domain at the
CRP promoter and found that b-catenin interacts with the
p50 subunit. We also used the technique of Chromatin
Conformation Capture (3C) (14,15) to identify possible
interaction sites forming chromatin loops to the CRP
promoter. Interestingly, we identiﬁed binding sites for
TCF/LEF which binds to b-catenin, not in the standard
upstream region but in the downstream of the CRP gene
(16). Most signiﬁcantly, we also showed that the interac-
tion of the p50 on the CRP promoter and the b-catenin
on CRP downstream was involved in CRP activation
upon TNF-a treatment. Our ﬁndings provide interesting
evidence that transcription of the CRP gene depends upon
the interaction between p50 and b-catenin and direct long
distance interactions of the bound DNA.
MATERIALS AND METHODS
Cellculture andtransfection
Cells of 293T were cultured in DMEM containing 10%
fetal bovine serum (BRL Life Technology, Inc.). HepG2
cells were cultured in MEM containing 10% fetal bovine
serum. Transfection of cells was performed using
lipofectAMINE transfection reagent (Invitrogen).
pCMV-b (50ng) was co-transfected in each case to
normalize transfection eﬃciency. After 24h of incubation,
cells were cultured under serum-free conditions for 2h
followed by treatment with 30ng/ml TNF-a for indicated
times. pSUPER-b-catenin (1.5mg) or pSUPER-p50 was
transiently transfected for knock down of p50 and
b-catenin protein. After 72h of transfection, cells were
cultured under serum-free conditions for 2h followed by
treatment with 30ng/ml TNF-a for 8h before harvest.
Reagents andantisera
Recombinant human TNF-a, phosphatase inhibitor cock-
tail and protease inhibitor cocktail were purchased from
Sigma-Aldrich. Restriction and modifying enzymes were
from Roche Molecular Biochemicals. Anti-p50 mouse
monoclonal antibody (sc-8414) and Anti-TCF-4 rabbit
polyclonal antibody (sc-13027) were purchased from
Santa Cruz Biotechnology. Anti-FLAG M2 mouse mono-
clonal antibody (F3165) was from Sigma-Aldrich. Anti-b-
catenin mouse monoclonal antibody (610154) was from
BD Transduction Laboratories. Anti-TCF-1 rabbit
polyclonal antibody was generated by KOMA
Biotechnology.
Plasmids
Human p50 expression clones were kindly provided by
Dr Young Mee Kim (Asan Medical Center). Human p65/
RelA expression clone were previously reported (17).
Stable b-catenin (S37A) was previously reported (18).
FLAG-p50 plasmid was composed of human p50 cDNA
(nucleotides 52–1200 of Genbank/Bank Accession
NM_003998) in the pCMV-tag2 mammalian expression
vector (Stratagene, La Jolla, CA, USA). BAC (bacterial
artiﬁcial chromosome) clones were purchased from
ResGen (Catalog no: RPCI-11.C. Clone ID: RP11-
806E24). To make pSUPER-b-catenin and pSUPER-
p50, speciﬁc oligonucleotides (listed in Table 1) were
synthesized (Bioneer) as previously reported (19,20). To
anneal the oligonucleotides, the mixture was incubated
at 958C for 5min, and was cooled slowly. This mixture
was ligated into pSUPER vector (Oligoengine) that had
been digested with BglII and HindIII.
Immunoprecipitation and western blot analysis
Whole-cell extracts were centrifuged at 12 000 r.p.m. for
15min to obtain clear lysates and incubated either with
anti-FLAG antibody or with normal rabbit serum for
2h, followed by the incubation with protein G-Agarose
beads (BRL Life Technologies) for 3h and precipitation.
Western blot analysis was previously described (21).
Chromatin immunoprecipitation (ChIP)
Cells of 293T were cultured under serum-free conditions
for 2h followed by the treatment with 30ng/ml TNF-a
for 1h. Cells were ﬁxed in 1% formaldehyde at room
temperature and stopped the cross-liking reaction in
125mM glycine. Cells were lysed with 200 ml lysis buﬀer
[20mM HEPES (pH 7.9), 10mM NaCl, 1mM DTT,
1mM PMSF, 10 ml protease inhibitor cocktail] for 15min
at 48C. Nonidet P-40 (5ml of 0.5%) was added and
centrifuged. The pellets were washed with lysis buﬀer
and resuspended in nuclear lysis buﬀer [20mM HEPES
(pH 7.9), 1.5mM MgCl2, 1mM EGTA, 1mM dithio-
threitol, 300 mM phenylmethylsulfonyl ﬂuroride, 10%
glycerol, 1% Triton X-100, phosphatase inhibitor cocktail
and protease inhibitor cocktail] and incubated for 30min
at 48C. Resuspended cells were sonicated (BRASON
soniﬁer 250, duty cycle 60%, power control 100% 12sec
2X), centrifuged for 10min and the supernatants were
collected. The chromatin fragments were then cleared
with 1 mg of preimmune serum and protein G-Sepharose
(30ml of 50% slurry in 1 PBS) for 2h at 48C.
Immunoprecipitation was performed for 12–24h with
anti-p50, anti-b-catenin or anti-Tcf-4 antibody at 48C.
Anti-GST or normal rabbit IgG was used as a control.
Following immunoprecipitation, 30ml of protein
G-Sepharose was added and incubated for 3h.
Sepharose beads were collected and washed sequentially
for 3min in low salt buﬀer [0.1% SDS, 1% Triton X-100,
2mM EDTA, 20mM Tris-HCl (pH 8.1), 150mM NaCl],
high salt buﬀer [0.1% SDS, 1% Triton X-100, 2mM
EDTA, 20mM Tris-HCl (pH 8.1), 500mM NaCl] and
LiCl wash buﬀer [0.25M LiCl, 1% NP-40, 1mM EDTA,
10mM Tris-HCl (pH 8.1)] three times. Beads were washed
three times with TE buﬀer and extracted with elution
buﬀer (1% SDS, 0.1M NaHCO3). Elutes were heated at
658C for 6h to reverse the formaldehyde cross-linking.
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ethanol precipitation. Puriﬁed DNA fragments were
ampliﬁed with PCR. Primers used in this assay are listed
in Table 1.
Chromosome conformation capture (3C)
Cells of 293T were cultured under serum-free conditions
for 2h followed by treatment with 30ng/ml TNF-a for 1h.
Cells of 1 10
7 were cross-linked with 2% formaldehyde
in 1  PBS (4.5ml) at room temperature for 10min. The
cross-linking reaction was stopped by adding glycine to
a ﬁnal concentration of 0.125M. Cells were washed with
1  PBS, resuspended in 1ml cell lysis buﬀer [10mM Tris
(pH 8.0), 10mM NaCl, 0.2% NP-40 and protease
inhibitors], and incubated on ice for 10min. Samples
were kept on ice from this point forward. Cell lysis was
completed with ten strokes of a Dounce homogenizer
(pestle A). Nuclei were washed with 0.5ml of the 1  BglII
restriction enzyme buﬀer and resuspended in 762 mlo f
BglII restriction enzyme buﬀer. SDS was added to a
ﬁnal concentration of 0.1% and incubated for 15–60min
at 378C while shaking. Triton X-100 was then added to
the ﬁnal concentration of 1%. Digestion was performed
with 800 U of BglII at 378C overnight. The reaction was
stopped by adding SDS to a ﬁnal concentration of 2%
and incubated at 658C for 30min. The samples (50ml)
were diluted into a 950 ml ligation reaction buﬀer (5ng/ml)
containing 1% Triton X-100, 1  ligase buﬀer (NEB) and
incubated for 1h at 378C. Ligation was started by adding
4000 U of T4 DNA Ligase (NEB) and incubated for 4h
at 168C. Reactions were stopped by adding EDTA to a
concentration of 10mM. Samples were treated with
Proteinase K (100mg) at 658C to reverse cross-links,
incubated with RNase A (0.5mg) for 30min at 378C,
extracted with phenol:chloroform:IAA 2 times, chloro-
form 2 times, and ethanol precipitated with glycogen.
Samples were redissolved in deionized water. Genomic
sequences of CRP locus (chr1:156475000-156525000) and
their BglII restriction enzyme sites are obtained from
UCSC genome browser (http://genome.ucsc.edu/cgi-bin/
hgGateway). PCR primers are designed by PREMIER
biosoft program (http://www.premierbiosoft.com/
netprımer/Netprlaunch/netprlaunch.html) and UCSC
In-Silico PCR program (http://genome.ucsc.edu/cgi-bin/
hgPcr?command=start). Primers are designed only for
non-repetitive sequences. To normalize the diﬀerences of
the primer eﬃciency, BAC control template was prepared
by digesting with BglII followed by the random ligation.
PCR reaction was performed with the control template in
parallel with 3C templates. To equalize for the diﬀerences
in template amount or quality, PCR at the CRP locus
were normalized to a control interaction at the GAPDH
locus. Primers used in this assay are listed in Table 1.
Cloning of 125 CRPLuc-2 and  125 CRP Luc-1-2
construct cloning
-125 CRP luciferase reporter was kindly provided by
Dr Irving Kushner (Case Western Reserve University). To
generate the chimeric reporter containing the downstream
elements of CRP gene, the genomic fragments were cloned
on the downstream of luciferase gene. Genomic DNA was
prepared from 293T cells and two genomic fragments are
ampliﬁed with two primer sets (12-1F, 12-2R and 12-2F,
12-2R in Table 1), which contain one or two TCF/
LEF-binding sites. PCR products were cloned in a
Table 1. Primers
Sequence
shRNA primer
pSUPER-b-catenin 50GATCCCGTGGGTGGTATAGAGGCTC
TTCAAGAGAGAGCCTCTATACCACC
CACTTTTTGGAAA-30
50AGCTTTTCCAAAAAGTGGGTGGTAT
AGAGGCTCTCTCTTGAAGAGCCTCT
ATACCACCCACGG-30
pSUPER-p5O 50GATCCCTATTAGAGCAACCTAAACA
TTCAAGAGATGTTTAGGTTGCTCT
AATATTTTTGGAAA-30
50AGCTTTTCCAAAAATATTAGAGCA
ACCTAAACATCTCTTGAATGTTTA
GGTTGCTCTAATAGG-30
RT-PCR primer
Forward 50-CCTATGTATCCCTCAAAGCA-30
Reverse 50-CCCACAGTGTATCCCTTCTT-30
Luciferase primer
12-1 F 50-TACTCTCATTCTATCATTATTCCAA-30
12-2 F 30-ATAACCTCTTTACGCCTCAGT-30
12-2 R 50-CTTCTATGCTTACAAATGGTTATC-30
3C-CRP primers
Upstream anchor 50-CTGTCCCACCACTCTCTATCTGA-30
Fragment 1 50-GACACATGAATAGTGGCTTTGCTC-30
Fragment 2 50-CATCGCAAAGAGGCTAAACTC-30
Fragment 3 50-GGGATATAATCTCAATCTCCTGGTG-30
Fragment 4 50-AGCAAAAGAGCAAAGGGAGA-30
Fragment 5 50-CTGATGCCTACTATAATGGATG
TATTTC-30
Fragment 6 50-ACCCAGTCCAGATTAGGTCAGG-30
Fragment 7 50-GGCTATCAACATTCATCTCCTCAT-30
Downstream anchor
Fragment 8 50-CTTAAATTCTATACGTAAGTGAGGGG
AT-30
Fragment 9 50-CGGTCCAAAAGAATCAGAATTT
GA-30
Fragment 10 50-GTGGAGTCTCTGAATCAGCCTTG-30
Fragment 11 50-GATTGACAAACAACAGAGCCTTG
AC-30
Fragment 12 50-CTGGTCTCTAAACATGGAGTTTT
CC-30
Fragment 13 50-AGATCCCCCATGAGTGATTTAG
TG-30
Fragment 14 50-CCCTCTTCACTAGGTATGAAGCA
AG-30
Fragment 15 50-CACTATCTGAGGTCATCTGAGG
AG-30
Fragment 16 50-GCTTCTGGGAATAAAGCAGGC-30
Fragment 17 50-CAACAGGGAAATCCTCGAATATG-30
3C-GAPDH primers
GAPDH 1 50-GTTTCCATAGGACCTGCTGCG-30
GAPDH 2 50-GTTTTACACTGG GCACTTGAG
GTC-30
ChIP-CRP primers
Fragment 4 Forward 50-TCTCCCTTTGCTCTTTTGCT-30
Fragment 4 Reverse 50-CAATAAGTTCCAATGAAATA
GACA-30
Fragment 12 Forward 50-ATAACCTCTTTACGCCTCAGT-30
Fragment 12 Reverse 50-CTTCTATGCTTACAAATGGTTATC-30
Fragment 13 Forward 50-GGCTGATGGACTTAGGTAATACT-30
Fragment 13 Reverse 50-TGACCAAACTGAGCGAACTC-30
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BamHI and SalI to clone into -125 CRP Luc reporter.
-125 CRP Luc-2 was constructed by cloning a BamHI/Sal
fragment having PCR product with 12-2F and 12-2R
primers, which contains second putative TCF/LEF-bind-
ing site within fragment 12. -125 CRP Luc-1-2 was
constructed by cloning a BamHI/Sal fragment having
PCR product by 12-1F and 12-2R primers which contains
ﬁrst and second putative TCF/LEF-binding site within
fragment 12. After cloning, -125 CRP Luc reporters were
cut by BamHI and used in luciferase assay in some cases.
Reverse transcription-PCR analysis
RNA was extracted with Trizol reagent (Invitrogen)
and reverse transcribed. Samples were ampliﬁed at
958C for 30s, 518C for 30s, 728C for 30s for 30
cycles. The primers for CRP were as follows. F,
50-CCTATGTATCCCTCAAAGCA-30 R, 50-CCCACAG
TGTATCCCTTCTT-30.
RESULTS
NF-iBp50 and b-catenin arerequired forCRP
genetranscription
Since CRP expression is stimulated by various cytokines,
we examined how TNF-a induces CRP expression.
RT-PCR analysis showed that TNF-a stimulated the
transcription of the CRP gene in both 293T and HepG2
cells (Figure 1A). When we used the -125 CRP Luc
reporter that contains the CRP promoter, luciferase
activity was also enhanced after TNF-a treatment in two
cell lines (data not shown). Since NF-kB is a key mediator
of the TNF-a-induced expression of many genes, and the
CRP promoter contains a non-consensus kB-binding site
(AAACTCCCTTA) on -50 to -40, we tested the eﬀect
of overexpressing either the p50 or the p65 subunit of
NF-kB on CRP mRNA expression. As shown by
RT-PCR analysis (Figure 1B) and luciferase assays with
the -125 CRP promoter (Figure 1C), overexpression of
p50 increased CRP promoter activity in the 293T cell line.
On the other hand p65 overexpression did not stimulate
the promoter activity. To conﬁrm that the p50 and p65
plasmids possessed the expected biological activity, we
determined the luciferase activity transcribed from
consensus kB sites (NF-kB Luc) in 293T cells. As
expected, overexpression of p65 markedly activated the
NF-kB-Luc reporter whereas overexpression of p50 did
not (Figure 1D). This suggests that the TNF-a-induced
CRP transcription may be dependent on the p50 subunit
of NF-kB acting on the non-consensus kB site in the -125
CRP promoter.
Because the p50 subunit of NF-kB lacks a transactiva-
tion domain, transcriptional activation by p50 alone is
unusual (7,22). We searched for a putative co-activator
that could provide p50 with a transactivation domain
during TNF-a signaling. Since TNF-a activates NF-kB
signaling and PI3-Kinase/Akt pathway by which b-catenin
nuclear translocation is activated, we chose b-catenin as
a putative binding partner for NF-kB p50 protein.
In addition, because several reports suggested that
b-catenin and NF-kB may physically interact in basal
level (23,24), we reasoned that b-catenin could provide the
transactivation domain to p50 subunit. We also showed
by RT-PCR analysis that b-catenin and p50 acted in
concert to enhance the transcription of the endogenous
CRP gene in the 293T and HepG2 cell lines (Figure 2A).
These results suggest that b-catenin contributes to
the transcriptional activation of NF-kB p50 on the
CRP promoter, and may thus act as a transcriptional
co-activator of the p50 subunit.
To establish the critical roles of the NF-kB p50 subunit
and b-catenin in CRP gene transcription, we knocked
down the expression of the two proteins using pSUPER-
shRNAs in HepG2 cells. To conﬁrm the eﬃcacy of the
shRNAs, we performed western blot analyses with anti-
p50 and anti-b-catenin antibodies (Figure 2B). The
shRNA for p50 greatly reduced the steady-state level of
the p50 precursor protein, p105, and lowered somewhat
the level of p50 protein. The shRNA for b-catenin caused
signiﬁcant reduction of the b-catenin protein level. We
next tested whether the shRNAs inhibited TNF-a-induced
CRP gene expression (Figure 2C). Knockdown of p50
resulted in a substantial reduction of CRP mRNA, which
can be explained by the major roles of the NF-kB p50 in
basal and activated CRP transcription. In addition,
reduction of CRP mRNA was also observed when
shRNA for b-catenin was introduced. These results
suggest that NF-kB p50 and b-catenin are important
components of TNF-a-induced CRP gene expression.
Figure 1. The NF-kB p50 subunit induces CRP transcription. (A) RT-
PCR analysis of CRP mRNA. Cells of 293T and HepG2 were
incubated with or without TNF-a for 6h after serum starvation.
GAPDH was used as a control. (B) RT-PCR analysis of CRP mRNA
after transfection of p50 or p65 subunit in 293T cells. (C) Luciferase
assay of the -125 CRP promoter in 293T cells. Cells were transfected
with the -125 CRP Luc reporter and co-transfected with either NF-kB
p50 or p65 expression vectors. After 24h luciferase activity was
determined and normalized with b-gal activity. It is shown as
relative luciferase activity. Results are the average of three
independent experiments. (D) Luciferase assay with the consensus
3X-kB Luc reporter.
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on theCRP promoter
There is some evidence that the p65 subunit of NF-kB
interacts physically with b-catenin (23,24). We tested
whether the p50 subunit interacts with b-catenin in the
course of TNF-a-induced CRP transcription. We asked if
TNF-a promoted the interaction between b-catenin and
p50 in vivo by performing co-immunoprecipitation assays
with FLAG-tagged p50-transfected 293T cells. Even
though there is some basal protein–protein interaction
between p50 and b-catenin, we found that one hour of
TNF-a treatment greatly increased the amount of
b-catenin which was co-immunoprecipitated by anti-
FLAG antibody (Figure 3A). Since we had shown that
TNF-a activates CRP expression by NF-kB p50 on the
CRP promoter, we tested if TNF-a causes recruitment of
p50 to the -125 CRP promoter. We performed chromatin
immunoprecipitation (ChIP) assays with anti-p50 anti-
body and primers speciﬁc for the -125 CRP promoter. As
shown in Figure 3B, binding of p50 to the -125 CRP
promoter was induced by TNF-a treatment. These results
indicate that the interaction between p50 and b-catenin
is critical for TNF-a-induced CRP gene transcription.
TNF-a-induced proximity oflong distance fragments
to CRP promoter
Chromosome conformation capture (3C) is a newly
developed technique that can eﬀectively map the long
distance interactions between promoter and regulatory
sites (14,15,25,26). Since most activation of gene expres-
sion involves changes of chromosome conformation,
we used the 3C technique to map TNF-a-induced
chromosome interaction sites near the CRP locus. 3C
uses sequential nuclear restriction enzyme digestion,
ligation and PCR-based quantiﬁcation of the ligated
DNA products to assess the proximity of diﬀerent
regions of a chromosome. Two restriction fragments
that are close together in the nucleus display a higher
cross-linking frequency and therefore a higher ligation
frequency than two fragments that are far apart.
Figure 4A shows the CRP locus and the BglII
restriction sites within 50kb of the locus. BglII was
chosen because its sites are evenly spaced along the CRP
gene and ﬂanking sequences. The segment between
fragments 7 and 8 contains the CRP promoter to which
NF-kB p50 binds. To test the eﬀect of TNF-a on the
proximity of regulatory elements to the CRP promoter,
we used an upstream anchor primer within the promoter
fragment in pairwise combinations with primers within
the fragments of the CRP gene (Figure 4B). All the PCR
reactions were performed in triplicate and averaged. The
3C analysis showed that, in the absence of TNF-a (open
bar), the proximity of each fragment (fragments 1–7) to
the CRP promoter decreased with distance. However,
after TNF-a treatment (solid bars), the proximity of
fragment 4 to the promoter increased (Figure 4C). We
then used the downstream anchor primer in pairwise
Figure 2. NF-kB p50 and b-catenin are indispensable for TNF-a-induced CRP expression. (A) RT-PCR analysis. Cells were transfected with
either NF-kB p50 and/or stable b-catenin expression vectors. (B) Western blot analysis after shRNA transfection. Cells were transfected with
either pSUPER vector (vec), pSUPER-p50 shRNA (p50) or pSUPER-b-catenin shRNA (b-catenin). Expression of p105 and p50 was analyzed
with anti-p50 antibody. Anti-b-catenin antibody was used to test for the knockdown of b-catenin. Anti-tubulin antibody was used as a control.
(C) RT-PCR analysis of CRP mRNA expression following shRNA transfection to HepG2 cells. After 72h, cells were incubated with or without
TNF-a for 6h. PCR bands were scanned with a densitometer and the density of the CRP band was normalized with that of GAPDH band and
is shown graphically. Relative density was presented in comparison to that of vector-transfected cells without TNF-a treatment. Results are
the average of three independent experiments.
Nucleic Acids Research, 2007, Vol. 35, No. 16 5515combination with primers within the BglII fragments
and found that TNF-a treatment (solid bar) greatly
increased the proximity of fragment 12 (Figure 4D and E).
All the 3C data were normalized by the control
BAC template and a GAPDH interaction. These results
suggest that TNF-a treatment brings fragments 4 and
12 in contact with the CRP promoter.
b-Catenin binds to thedownstream region of CRP gene
The induced proximity of chromosomal regions may be
caused by interactions between proteins bound to
chromosomal sites that are far apart (26). We hypothe-
sized that the 3C interaction observed after TNF-a
treatment was due to interaction between p50 bound
to the -125 CRP promoter (Figure 3B) and b-catenin
bound to the distant regulatory region(s). Since b-catenin
itself does not bind to DNA but forms a DNA-bound
complex with TCF-4 (16), we searched for putative
TCF/LEF-binding sites within fragments 4 and 12.
Chromatin immunoprecipitation assays were performed
with a probe speciﬁc for fragment 4 (Figure 5A). TNF-a
treatment did not increase the binding of b-catenin and
TCF-4 within fragment 4, which probably reﬂects the
absence of TCF/LEF-binding sites in this fragment. In
contrast, six putative TCF/LEF-binding sites were found
within fragment 12, and ChIP assays with primers speciﬁc
for the second putative TCF/LEF-binding sites within
fragment 12 showed that the binding of p50, b-catenin
and TCF-4 was greatly increased by TNF-a treatment
(Figure 5B). This suggests that the -125 CRP promoter
bound p50 and the distal regulatory sites (fragments 12)
bound b-catenin are in close proximity. We used fragment
13 as a negative control for the ChIP experiments since
the 3C experiment showed that its proximity to the
promoter did not increase after TNF-a treatment
(Figure 5C).
Since the previous ChIP data suggest that the second
putative TCF/LEF-binding site might be responsible for
the b-catenin binding to fragment 12, we tested whether
the site is responsible for the activation of CRP transcrip-
tion. We designed the -125 CRP luciferase reporters with
the putative TCF/LEF-binding sites from fragment 12
located in the downstream of the gene and named them
as -125 CRP Luc-2 and -125 CRP Luc-1-2. Figure 6B
showed that the luciferase activities of the -125 CRP Luc
reporters containing one or two putative TCF/LEF-
binding site were increased to 2-fold in comparison to
that of -125 CRP Luc reporter having no TCF/LEF-
binding site. Protein levels of expressed p50 and b-catenin
was not diﬀerent in these samples as shown by immuno-
blotting with anti-FLAG, anti-b-catenin antibody
(Figure 6B). This result suggests that CRP transcriptional
activity is enhanced by the fragment 12 which has
putative TCF/LEF-binding sites.
DISCUSSION
We showed here that after TNF-a treatment NF-kB
p50 activates CRP expression by associating with
b-catenin/TCF bound to a distant downstream region of
the CRP gene. The NF-kB p50 subunit lacks a transacti-
vation domain, but we present evidence for a direct
interaction between p50 and b-catenin that could provide
the p50 with a transactivation domain after TNF-a
signaling. We also have evidence that shRNA-mediated
suppression of b-catenin signiﬁcantly reduces TNF-a-
induced CRP expression as well as expression of other
p50-dependent genes (Choi et al., unpublished data).
These results suggest that TNF-a-induced nuclear trans-
location of b-catenin could serve as a transcriptional
co-activator for the p50 subunit.
There is much evidence that PI3-kinase/Akt activation
is involved in nuclear translocation of b-catenin following
GSK-3b inactivation. It is reported that lipopolysaccha-
ride activates Akt1 in alveolar macrophages resulting in
nuclear accumulation and transcriptional activation of
b-catenin (27). Just as Wnt-activated b-catenin functions
as a transcription co-activator for TCF/LEF proteins,
activation of b-catenin by PI3-Kinase/Akt is reported to
provide a transcriptional co-activator function for the
androgen receptor (28). We also showed here that
b-catenin is involved in the activation of CRP gene with
NF-kB p50 protein. If nuclear b-catenin plays a role as a
transcriptional co-activator for p50, it has to directly or
indirectly interact with the p50 subunit. Several reports
have suggested a possible relation between b-catenin and
NF-kB (23,24,29) but there has been no deﬁnitive evidence
that TNF-a induced interaction between them. We
showed here for the ﬁrst time that TNF-a signiﬁcantly
increased the extent of interaction between b-catenin and
NF-kB p50 subunit. Full understanding of TNF-a-
induced CRP transcription may require the identiﬁcation
of the intermediate proteins as well as signal pathways
leading to the strong interaction between NF-kB p50 and
b-catenin (30).
Transcription is mediated by the binding of speciﬁc
transcription factors to regulatory sequences. Long-range
interactions between promoter and regulatory elements
are important for high level expression of target
Figure 3. NF-kB p50 and b-catenin interact on the CRP promoter.
(A) Co-immunoprecipitation assay. Cells of 293T were transfected with
a FLAG-tagged p50 expression construct. After 24h, cells were
incubated with or without TNF-a for 1h. Whole cell extracts were
prepared, immunoprecipitated (IP) with anti-FLAG antibody, and the
precipitated proteins analyzed by immunoblotting (IB) with anti-b-
catenin or anti-FLAG antibody. Input: 8% of whole cell extract.
Precipitation with IgG was used as a control. (B) Chromatin
immunoprecipitation assays with anti-p50 and anti-b-catenin antibodies
and the -125 CRP promoter primer. Cells of 293T were treated with
TNF-a for 1h and analyzed the binding of p50 and b-catenin to the
CRP promoter.
5516 Nucleic Acids Research, 2007, Vol. 35, No. 16genes, and may cause looping of chromatin as well as
protein–protein interactions (31–33). Since nuclear
b-catenin is engaged in TCF/LEF protein complex (34),
we screened the genomic sites induced to interact with
CRP promoter by 3C technology. We also searched
for the TCF/LEF-binding sites and identiﬁed a fragment
12 ( 3.3kb downstream from the promoter) as the
binding site of b-catenin by ChIP analysis. If nuclear
b-catenin binds TCF/LEF which already occupies a
speciﬁc sequence in fragment 12, it is likely that
TNF-induced binding of b-catenin to the CRP promoter
is caused by the looping of chromatin between
promoter and the TCF/LEF-binding elements in
fragment 12.
Our 3C data indicate that the proximity of fragments 4
and 12 to the CRP promoter was increased by TNF-a
treatment. However, putative TCF/LEF-binding sites do
not exist within fragment 4 and we could not detect any
TNF-a-induced binding of b-catenin to fragment 4 by
ChIP analysis. This suggests that the interaction between
fragment 4 and the CRP promoter may be caused by
interaction of p50 with some other protein.
Figure 4. 3C reveals putative chromosome interaction sites near the CRP gene. (A) Schematic representation of the CRP locus. CRP locus
fragments generated by BglII digestion of genomic DNA and used for 3C analysis are numbered. The fragment containing the CRP promoter is also
indicated. Vertical arrows depict the individual BglII sites and the sizes indicate the distances between individual BglII sites. The CRP gene (CRP)
is indicated by the boxes (exons) and the line between them (intron), and the orientation of the gene is depicted by the arrows below. The
primers used for the 3C and ChIP analysis are also indicated. (B) 3C analysis of the upstream regions of the CRP gene. Numbers denote the
3C-analyzed BglII fragments. N; No treated cells,T; TNF-a-treated cells. (C) Graphical representation of 3C data for (B). Each signal was
normalized to control BAC templates and a GAPDH interaction. (D) 3C analysis of the downstream regions of the CRP gene. Numbers denote the
3C-analyzed BglII fragments. N; No treated cells, T; TNF-a-treated cells. (E) Graphical representation of 3C data for (D). Each signal was
normalized to control BAC templates and a GAPDH interaction. No; Untreated cells (Open box). TNF; TNF-a-treated cells (Solid box).
Nucleic Acids Research, 2007, Vol. 35, No. 16 5517Since NF-kB p50 protein may be involved in regulating
inﬂammatory genes such as CRP, we propose here
that during TNF-a-induced inﬂammation, NF-kB p50
induces inﬂammatory genes by interacting with b-catenin
bound to downstream region of the gene. This idea
may provide a missing piece of the puzzle posed
by the complex cellular NF-kB/b-catenin regulatory
network.
Figure 5. TNF-a-induced b-catenin occupancy on fragment 12. Chromatin immunoprecipitation assay with a fragment 4 primer (A) fragment 12
primer (B) and fragment 13 primer (C). PCR bands were scanned with a densitometer and the densities of p50 and b-catenin-bound bands relative
to GST bands are shown graphically. Open box: untreated cells (No). Solid box: TNF-a-treated cells (TNF). Results are the average of three
independent experiments.
Figure 6. The second putative TCF/LEF-binding site within fragment 12 enhanced the CRP transcription. (A) Schematic representation of the
constructs with or without putative TCF/LEF-binding sites. -125 CRP Luc (no TCF site); -125 CRP Luc (with second putative TCF/LEF site, shown
as 2; -125 CRP Luc (with ﬁrst and second putative TCF/LEF site, as shown as 1-2). (B) Cells were co-transfected with either -125 CRP Luc reporters
or NF-kB p50 and stable b-catenin expression vectors. After 24h, relative luciferase activities were determined. Results are the average of three
independent experiments. Western blot analyses for the expression of NF-kB p50 and stable b-catenin were also shown. Expression of p50 and
b-catenin was analyzed with anti-FLAG and anti-b-catenin antibody.
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